Epidermal growth factor receptor inhibitors are anti-tumour agents that are frequently used for the treatment of neoplastic disorders. In addition to their cutaneous adverse effects, these drugs can rarely lead to erosive pustular dermatosis of the scalp. We report a case of a 67-year-old female who developed erosive pustular dermatosis of the scalp after being started on erlotinib from a trichoscopic perspective, which has been described in literature only once till now.
NazzaroGGiacaloneSBortoluzziP, et al. Erosive pustular dermatosis of the scalp induced by gefitinib: case and review of the literature. Dermatol Online J2021; 27: 13030.
2.
AgeroALDuszaSWBenvenuto-AndradeC, et al. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol2006; 55: 657–670.
3.
FukuiTKitamuraHHaradaK, et al. Trichoscopic findings of erosive pustular dermatosis of the scalp associated with gefitinib. Case Rep Dermatol2017; 9: 44–49.
4.
BartholomewCEastlakeLDunnP, et al. EGFR targeted therapy in lung cancer; an evolving story. Respir Med Case Rep2017; 20: 137–140.
5.
SoniKKumarTPandeyM.Gallbladder cancer with EGFR mutation and its response to GemOx with erlotinib: a case report and review of literature. World J Surg Oncol2020; 18: 153.
6.
TodaNFujimotoNKatoT, et al. Erosive pustular dermatosis of the scalp-like eruption due to gefitinib: case report and review of the literature of alopecia associated with EGFR inhibitors. Dermatology2012; 225: 18–21.
7.
MakKKChanSY.Epidermal growth factor as a biologic switch in hair growth cycle. J Biol Chem2003; 278: 26120–26126.
